Wegovy was designed readily available in Europe’s most obese nation on Sept. 4, in what Novo called a “controlled and limited start”.The Norwegian Medicines Agency stated in January 2023 it wouldn't subsidise the drug, stating the price would be too higher in relation to your documented wellness consequences.6Wresearch could be the premier, o